<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501354</url>
  </required_header>
  <id_info>
    <org_study_id>19-08-1018</org_study_id>
    <nct_id>NCT04501354</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients</brief_title>
  <official_title>Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients (Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmad Jabir Rahyussalim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of the allogeneic mesenchymal cell from umbilical&#xD;
      cord in improving the quality and quantity of spinal density of osteoporosis patients proven&#xD;
      by the results of Bone Mass Density (BMD) examination compared to baseline and evaluate&#xD;
      improvement of quality of pain with visual analog scale (VAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, preventive and therapeutic strategies for osteoporosis patients are based on&#xD;
      calcium and vitamin D supplementation, the use of pharmacological agents that inhibit bone&#xD;
      resorption such as bisphosphonates, and sometimes calcitonin. Although bisphosphonates have&#xD;
      been found to reduce osteoporosis, clinical use for these drugs has been limited because of&#xD;
      its potential to produce serious side effects, such as mandibular osteonecrosis and atypical&#xD;
      femoral fractures. Therefore, new therapeutic strategies for osteoporosis are needed.&#xD;
&#xD;
      This study will assess the effectiveness of the allogeneic mesenchymal cell from umbilical&#xD;
      cord. Patients who have received mesenchymal stem cell therapy (MSC) are expected to have&#xD;
      positive effects such as reduced pain sensation in the back assessed by Visual Analog Scale&#xD;
      (VAS), improvement in the range of motion (ROM), improving the quality of osteoporosis&#xD;
      patients's bone proven by the results of Bone Mass Density (BMD) and improvement in patients'&#xD;
      quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mass Density (BMD)</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement of spinal density in osteoporosis patients proven by the results of Bone Mass Density (BMD).&#xD;
Above Standard Deviation (SD) (-1) means normal&#xD;
Between SD (-1) and (-2.5) is classified as osteopenia. Osteopenia is a condition when bone density is lower than the average, but not as low as osteoporosis.&#xD;
Below SD (-2.5) is categorized as osteoporosis.&#xD;
The numbers are expected to be higher after MSC implantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluates pain quality using Visual Analog Scale (VAS) from 0 - 10. Zero is no pain at all, one is the the least pain and ten is the most painful. The numbers are expected to be lower after MSC implantation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>UC-Mesenchymal Stem Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic Mesenchymal Stem Cell from umbilical cord</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Stem Cell</intervention_name>
    <description>Mesenchymal Stem Cell + NaCl 0,9% 2ml</description>
    <arm_group_label>UC-Mesenchymal Stem Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male patients older than 50 yrs old.&#xD;
&#xD;
          2. Female patients older than 40 years old.&#xD;
&#xD;
          3. Patients enrolled in Cipto Mangunkusumo Hospital with osteoporosis confirmed by BMD&#xD;
             test.&#xD;
&#xD;
          4. Patients with no history of autoimun disease (SLE, Addison's disease, Chron's disease)&#xD;
             and other diseases related to osteoporosis.&#xD;
&#xD;
          5. Patients with no history of consuming drug related osteoporosis.&#xD;
&#xD;
          6. No active infection confirmed by HbsAg, HIV, CMV, Rubella and Toxoplasma examination.&#xD;
&#xD;
          7. Agree to participate the study by signing informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with autoimun diesasde (SLE, Addison's diesase, Chron's disease and other&#xD;
             osteoporosis related disease.&#xD;
&#xD;
          2. Patients under immunosuppressive, anticoagulant or corticosteroid treatment.&#xD;
&#xD;
          3. Paralysis patients after surgical treatment&#xD;
&#xD;
          4. Patients under 20 years old&#xD;
&#xD;
          5. Declined to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmad Jabir Rahyussalim</last_name>
    <phone>+62811819466</phone>
    <email>rahyussalim71@ui.ac.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tri Kurniawati, S.Si</last_name>
    <phone>+628121134311</phone>
    <email>trie3k@ui.ac.id</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Jabir Rahyussalim, MD,PhD,SpOT</last_name>
      <phone>+62811819466</phone>
      <email>rahyussalim71@ui.ac.id</email>
    </contact>
    <contact_backup>
      <last_name>Trie K Kurniawati, SSi</last_name>
      <phone>+628121134311</phone>
      <email>trie3k@ui.ac.id</email>
    </contact_backup>
    <investigator>
      <last_name>Ahmad Jabir Rahyussalim, MD,PhD,SpOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 2, 2020</study_first_submitted>
  <study_first_submitted_qc>August 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Ahmad Jabir Rahyussalim</investigator_full_name>
    <investigator_title>Orthopaedic and Traumatology Specialist, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

